ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Circulating serum microRNAs in kidney transplant recipients with post-transplant malignancies.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPost-transplant malignancies are a major cause of long-term morbidity and mortality in kidney transplant recipients. Reliable non-invasive biomarkers may improve post-transplant oncological surveillance. Circulating microRNAs have emerged as promising candidate biomarkers in several malignancies, but their role in kidney transplant recipients remains poorly characterized.
objectiveTo compare circulating serum microRNA concentrations between kidney transplant recipients with and without post-transplant malignancies and to identify candidate microRNAs associated with the presence of malignancy.
methodsThis exploratory pilot study included 40 kidney transplant recipients (27 with post-transplant malignancies and 13 cancer-free controls). Serum concentrations of five preselected microRNAs (miR-21, miR-146a, miR-196a, miR-203a, and miR-221) were quantified using droplet digital PCR. Group comparisons were performed using the Mann-Whitney U test, and receiver operating characteristic (ROC) curve analysis was used to evaluate discriminatory performance.
resultsSerum concentrations of miR-21 and miR-196a were significantly higher in recipients with post-transplant malignancies than in cancer-free controls (both p = 0.003). Serum miR-221 concentrations were also significantly elevated (p = 0.020), whereas no significant differences were observed for miR-146a or miR-203a. ROC analysis demonstrated acceptable discriminatory performance for miR-21 (AUC 0.742, 95%CI 0.601-0.883) and miR-196a (AUC 0.771, 95%CI 0.619-0.922).
conclusionsCirculating serum miR-21 and miR-196a were significantly associated with the presence of post-transplant malignancy in kidney transplant recipients, while miR-221 showed an additional exploratory association. These findings support further investigation of circulating microRNAs as candidate non-invasive biomarkers in transplant oncology. Larger prospective studies are required to validate these observations.
Indexed as
Identifiers
42412279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.